FILE 'MEDLINE' ENTERED AT 12:57:53 ON 07 JAN 2008

FILE LAST UPDATED: 5 Jan 2008 (20080105/UP). FILE COVERS 1950 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot 144

L44 ANSWER 1 OF 7 MEDLINE on STN

AN 2005246876 MEDLINE

DN PubMed ID: 15887106

- TI Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea.
- AU Paton Adrienne W; Jennings Michael P; Morona Renato; Wang Hui; Focareta Antonio; Roddam Louise F; Paton James C
- CS School of Molecular and Biomedical Science, University of Adelaide, South Australia, Australia.
- SO Gastroenterology, (2005 May) Vol. 128, No. 5, pp. 1219-28. Journal code: 0374630. ISSN: 0016-5085.
- CM Comment in: Gastroenterology. 2005 May; 128(5):1509-12. PubMed ID: 15887131

CY United States

DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Abridged Index Medicus Journals; Priority Journals

of enterotoxigenic Escherichia coli-induced

EM 200507

- ED Entered STN: 12 May 2005 Last Updated on STN: 6 Jul 2005 Entered Medline: 5 Jul 2005
- BACKGROUND & AIMS: We have developed a therapeutic strategy for AΒ gastrointestinal infections that is based on molecular mimicry of host receptors for bacterial toxins on the surface of harmless gut bacteria. The aim of this study was to apply this to the development of a recombinant probiotic for treatment and prevention of diarrheal disease caused by enterotoxigenic Escherichia coli strains that produce heat-labile enterotoxin. METHODS: This was achieved by expressing glycosyltransferase genes from Neisseria meningitidis or Campylobacter jejuni in a harmless Escherichia coli strain (CWG308), resulting in the production of a chimeric lipopolysaccharide capable of binding heat-labile enterotoxin with high avidity. RESULTS: The strongest heat-labile enterotoxin binding was achieved with a construct (CWG308:pLNT) that expresses a mimic of lacto-N-neotetraose, which neutralized > or = 93.8% of the heat-labile enterotoxin activity in culture lysates of diverse enterotoxigenic Escherichia coli strains of both human and porcine origin. When tested with purified heat-labile enterotoxin, it was capable of adsorbing approximately 5% of its own weight of toxin. Weaker toxin neutralization was achieved with a construct that mimicked the ganglioside GM2. Preabsorption with, or coadministration of, CWG308:pLNT also resulted in significant in vivo protection from heat-labile enterotoxin-induced fluid secretion in rabbit ligated ileal loops. CONCLUSIONS: Toxin-binding probiotics such as those described here have considerable potential for prophylaxis and treatment

```
travelers' diarrhea.
CT
      Adrenal Glands: CY, cytology
      Bacterial Toxins: ME, metabolism
      Campylobacter jejuni: GE, genetics
      Cells, Cultured
        Cholera Toxin: ME, metabolism
       *Diarrhea: MI, microbiology
       *Diarrhea: PC, prevention & control
       Enterotoxins: ME, metabolism
       *Escherichia coli: CL, classification
       *Escherichia coli: GE, genetics
        Escherichia coli: ME, metabolism
      Glycosyltransferases: GE, genetics
      Ileum: MI, microbiology
      Lipopolysaccharides: ME, metabolism
      Neisseria meningitidis: GE, genetics
     *Probiotics: PD, pharmacology
      Rabbits
      Recombinant Proteins: GE, genetics
     9012-63-9 (Cholera Toxin)
RN
     0 (Bacterial Toxins); 0 (Enterotoxins); 0 (Lipopolysaccharides);
CN
     O (Recombinant Proteins); O (heat stable toxin (E coli
     )); EC 2.4.- (Glycosyltransferases)
L44
    ANSWER 2 OF 7
                       MEDLINE on STN
     2001060702
AN
                    MEDLINE
     PubMed ID: 10965049
DN
     Common architecture of the primary galactose binding sites of Erythrina
ΤI
     corallodendron lectin and heat-labile enterotoxin from
     Escherichia coli in relation to the binding of branched
     neolactohexaosylceramide.
ΑU
     Teneberg S; Berntsson A; Angstrom J
     Institute of Medical Biochemistry, Goteborg University, P.O. Box SE 405 30
CS
     Goteborg, Sweden.
     Journal of biochemistry, (2000 Sep) Vol. 128, No. 3, pp. 481-91.
SO
     Journal code: 0376600. ISSN: 0021-924X.
CY
     Japan
DT
     (COMPARATIVE STUDY)
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
FS
     Priority Journals
EM
     200012
ED
     Entered STN: 22 Mar 2001
     Last Updated on STN: 18 Dec 2002
     Entered Medline: 22 Dec 2000
     The heat-labile enterotoxin from Escherichia
AB
     coli (LT) is responsible for so-called traveller's
     diarrhea and is closely related to the cholera toxin (CT). Toxin
     binding to GM1 at the epithelial cell surface of the small intestine
     initiates the subsequent diarrheal disease. However, LT has a
     broader receptor specificity than CT in that it also binds to
     N-acetyllactosamine-terminated structures. The unrelated lectin from
     Erythrina corallodendron (ECorL) shares this latter binding property.
     findings that both ECorL and porcine LT (pLT) bind to lactose as well as
     to neolactotetraosylceramide suggests a common structural theme
     in their respective primary binding sites. Superimposing the terminal
     galactose of the lactoses in the respective crystal structures of pLT and
```

ECorL reveals striking structural similarities around the galactose

despite the lack of sequence and folding homology, whereas the interactions of the penultimate GlcNAcb3 in the neolactotetraosylceramide differ. The binding of branched
neolactohexaosylceramide to either protein reveals an enhanced affinity relative to neolactotetraosylceramide. The b3-linked branch is found to bind to the primary Gal binding pocket of both proteins, whereas the b6-linked branch outside this site provides additional interactions in accordance with the higher binding affinities found for this compound. While the remarkable architectural similarities of the primary galactose binding sites of pLT and ECorL point to a convergent evolution of these subsites, the distinguishing structural features determining the overall carbohydrate specificities are located in extended binding site regions. In pLT, Argl3 is thus found to play a crucial role in enhancing the affinity not only for N-acetyllactosamineterminated structures but also for GM1 as compared to human LT (hLT) and CT. The physiological relevance of the binding of N-acetyllactosaminecontaining glycoconjugates to LT and ECorL is briefly discussed. Amino Sugars: ME, metabolism Animals *Antigens, CD *Bacterial Toxins: ME, metabolism Crystallography, X-Ray *Enterotoxins: ME, metabolism *Erythrina: ME, metabolism *Escherichia coli: ME, metabolism *Escherichia coli Proteins *Galactose: ME, metabolism Humans Hydrogen Bonding Isotope Labeling *Lactosylceramides: ME, metabolism *Lectins: ME, metabolism Ligands Magnetic Resonance Spectroscopy Models, Molecular Plant Lectins *Plants, Medicinal Protein Conformation Structure-Activity Relationship 26566-61-0 (Galactose); 32181-59-2 (N-acetyllactosamine); 4682-48-8 (CDw17 antigen) 0 (Amino Sugars); 0 (Antigens, CD); 0 (Bacterial Toxins); 0 (Enterotoxins); 0 (Escherichia coli Proteins); 0 (Lactosylceramides); 0 (Lectins); 0 (Ligands); 0 (Plant Lectins); 0 (enterotoxin LT) ANSWER 3 OF 7 MEDLINE on STN 97403073 MEDITNE PubMed ID: 9258442 Immobilization of reducing sugars as toxin binding agents. Nilsson U J; Heerze L D; Liu Y C; Armstrong G D; Palcic M M; Hindsgaul O Department of Chemistry, University of Alberta, Edmonton, Canada. Bioconjugate chemistry, (1997 Jul-Aug) Vol. 8, No. 4, pp. 466-71. Journal code: 9010319. ISSN: 1043-1802. United States Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) English

CT

RN

CN

L44

ΑN

DN

TI AU

CS

SO

CY

DT

LA

```
FS
     Priority Journals
EΜ
     199710
ED
     Entered STN: 24 Oct 1997
     Last Updated on STN: 24 Oct 1997
     Entered Medline: 10 Oct 1997
     A simple and economical procedure for the attachment of reducing sugars to
AB
     aminated solid supports has been developed. Reaction of the amino groups
     on the solid support with p-nitrophenyl chloroformate, followed by
     1,6-hexanediamine, yields a chain-extended amine to which reducing sugars
     can be attached while remaining accessible to macromolecules.
     Immobilization of the reducing sugars involves a simple incubation
     followed by trapping of the resulting glycosylamine with acetic anhydride
     and recovery of the unreacted sugar by filtration. This technique was
     used to immobilize lactose and sialyllactose onto silylaminated
     Chromosorb P, producing solid supports that effectively neutralized the
     activity of cholera toxin from Vibrio cholerae and heat-labile
     enterotoxin of enterotoxigenic Escherichia
     coli. The general applicability of such solid supports for toxin
     neutralization was further demonstrated by immobilization of the
     enzymatically synthesized alpha Gal(1-3) beta Gal(1-4)Glc trisaccharide,
     which produced a support that efficiently neutralized toxin A of
     Clostridium difficile. The results from this study suggest that these
     solid supports have the potential to serve as inexpensive therapeutics for
     bacterial toxin-mediated diarrheal diseases.
CT
      Animals
     *Bacterial Toxins: ME, metabolism
      CHO Cells
      Carbohydrate Sequence
       *Cholera Toxin: ME, metabolism
      Cricetinae
       *Enterotoxins: ME, metabolism
       Escherichia coli: CH, chemistry
       *Escherichia coli Proteins
      Molecular Sequence Data
     *Oligosaccharides: CH, chemistry
      Oligosaccharides: ME, metabolism
      Oxidation-Reduction
      Protein Binding
RN
     9012-63-9 (Cholera Toxin)
     0 (Bacterial Toxins); 0 (Enterotoxins); 0 (Escherichia
CN
     coli Proteins); 0 (Oligosaccharides); 0 (enterotoxin
     LT); 0 (tcdA protein, Clostridium difficile)
    ANSWER 4 OF 7
L44
                       MEDLINE on STN
ΑN
     95252586
                 MEDLINE
     PubMed ID: 7766178
DN
ΤI
     Inhibition of cholera toxin by human milk fractions and
     sialyllactose.
ΑU
     Idota T; Kawakami H; Murakami Y; Sugawara M
CS
     Technical Research Institute, Snow Brand Milk Products Co., Ltd., Saitama,
     Japan.
SO
     Bioscience, biotechnology, and biochemistry, (1995 Mar) Vol. 59,
     No. 3, pp. 417-9.
     Journal code: 9205717. ISSN: 0916-8451.
CY
     Japan
DT
     (IN VITRO)
     Journal; Article; (JOURNAL ARTICLE)
     English
LA
FS
     Biotechnology
     199506
EM
```

```
ED
     Entered STN: 9 Aug 1995
     Last Updated on STN: 9 Aug 1995
     Entered Medline: 8 Jun 1995
     The effects of human milk fractions on clolera toxin B subunit binding to
AB
     monosialoganglioside 1 (GM1) were investigated. Human milk, human defatted milk, whey, and a low-molecular-weight fraction of human milk
     inhibited the binding, but casein did not inhibit it. The inhibitory
     activity of whey from bovine-milk-based infant formula was less than that
     of whey from human milk. Differences in composition between human and
     bovine whey seemed to influence the extent of the inhibitory activity.
     Sialylated oligosaccharides were considered to be the possible components
     that inhibited cholera toxin. The effects of sialyllactose, a
     predominant sialylated component of human milk, on cholera toxin-induced
     diarrhea were investigated by the rabbit intestinal loop method.
     Sialyllactose inhibited the cholera toxin inducing fluid
     accumulation, although neither sialic acid nor lactose had an effect on
     it. The results suggest that sialyllactose is responsible for
     the inhibitory activity of milk on cholera toxin.
CT
     Check Tags: Male
      Animals
      Binding, Competitive: DE, drug effects
      Body Fluids: DE, drug effects
       *Cholera Toxin: AI, antagonists & inhibitors
      G(M1) Ganglioside: PD, pharmacology
      Humans
      Intestines: DE, drug effects
      Intestines: ME, metabolism
     *Lactose: AA, analogs & derivatives
      Lactose: PD, pharmacology
     *Milk, Human: CH, chemistry
      Oligosaccharides: IP, isolation & purification
      Oligosaccharides: PD, pharmacology
      Rabbits
     *Sialic Acids: PD, pharmacology
RN
     35890~38-1 (N-acetylneuraminoyllactose); 37758-47-7 (G(M1)
     Ganglioside); 63-42-3 (Lactose); 9012-63-9 (Cholera Toxin)
CN
     0 (Oligosaccharides); 0 (Sialic Acids)
L44
     ANSWER 5 OF 7
                       MEDLINE on STN
AN
     93293800
                  MEDLINE
DN
     PubMed ID: 8514738
TΙ
     Postnatal change of pig intestinal ganglioside bound by
     Escherichia coli with K99 fimbriae.
ΑU
     Yuyama Y; Yoshimatsu K; Ono E; Saito M; Naiki M
CS
     Faculty of Veterinary Medicine, Hokkaido University.
SO
     Journal of biochemistry, (1993 Apr) Vol. 113, No. 4, pp. 488-92.
     Journal code: 0376600. ISSN: 0021-924X.
CY
     Japan
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
     Priority Journals
FS
EΜ
     199307
ED
     Entered STN: 6 Aug 1993
     Last Updated on STN: 6 Aug 1993
     Entered Medline: 22 Jul 1993
AB
     Enterotoxigenic Escherichia coli possessing
     K99 fimbriae (E. coli K99) causes diarrhea
     in piglets of less than 1 week old. The first stage of the bacterial
     infection is adhesion by the fimbriae on the small intestinal mucosa and
```

the adhesion is followed by colony formation. K99 fimbriae bind specifically to N-glycolylneuraminyl-lactosylceramide, GM3(NeuGc) [Ono, E. et al. (1989) Infect. Immun. 57,907-911]. We examined the postnatal change of the content and the molecular species of GM3(NeuGc) in the small intestinal mucosa of 0- to 14-day-old piglets and adult pigs. GM3(NeuGc) was a major ganglioside of piglet intestinal mucosa. GM3(NeuGc) content was maximal at birth and gradually decreased to 1/16 in adult animals (5 months old). The ceramide moiety of piglet intestinal GM3(NeuGc) was characterized by the presence of 2-hydroxylated palmitic acid. 125I-labeled bacteria strongly bound to GM3(NeuGc) containing 2-hydroxylated palmitic acid and phytosphingosine compared with GM3(NeuGc) containing any other ceramide moiety. The time when this particular GM3(NeuGc) appears coincides with the time that the infection occurs, and it may explain the susceptibility of newborn piglets to E. coli K99 infection. Animals Animals, Newborn Chromatography, Thin Layer Enterotoxins *Escherichia coli: PY, pathogenicity *Escherichia coli Infections: MI, microbiology *G(M3) Ganglioside: AA, analogs & derivatives G(M3) Ganglioside: ME, metabolism Gangliosides: ME, metabolism *Intestinal Diseases: MI, microbiology *Intestinal Mucosa: ME, metabolism *Intestinal Mucosa: MI, microbiology Intestine, Small: ME, metabolism Intestine, Small: MI, microbiology Swine 69345-49-9 (N-glycolylneuraminyllactosylceramide) 0 (Enterotoxins); 0 (G(M3) Ganglioside); 0 (Gangliosides) ANSWER 6 OF 7 MEDLINE on STN 89339746 MEDLINE PubMed ID: 2503449 Hemagglutinating properties of Shigella dysenteriae type 1 and other Shigella species. Qadri F; Haq S; Ciznar I Laboratory Sciences Division, International Centre for Diarrhoeal Disease and Research, Bangladesh. Infection and immunity, (1989 Sep) Vol. 57, No. 9, pp. 2909-11. Journal code: 0246127. ISSN: 0019-9567. United States Journal; Article; (JOURNAL ARTICLE) English Priority Journals 198909 Entered STN: 9 Mar 1990 Last Updated on STN: 9 Mar 1990 Entered Medline: 15 Sep 1989 Strains of Shigella dysenteriae type 1 cultured in Casamino Acids-yeast extract broth medium in the presence of 1 mM calcium chloride at 37 degrees C for 22 h induced hemagglutination of erythrocytes that was inhibited by N-acetylneuraminic acid, N-acetylneuramin -lactose, and alpha 1-glycoprotein. The hemagglutination was heat labile, and the absence of cell-surface appendages suggested a nonfimbrial adhesin(s). Under the same conditions, strains of Shigella

CT

RN

CN

L44

AN

DN

ΤI

ΑU

CS

SO

CY

DT

LA

FS

EΜ

ED

AB

flexneri (types 1a, 1b, 2a, and 2b) showed N-acetylneuraminic

```
acid-resistant hemagglutination of erythrocytes.
CT
      Animals
      Cattle
      Culture Media: AN, analysis
      Guinea Pigs
      Haplorhini
     *Hemacglutination Tests
      Humans
      Rabbits
      Sheep
        Shigella dysenteriae: GD, growth & development
       *Shigella dysenteriae: IM, immunology
      Swine
CN
     0 (Culture Media)
L44
     ANSWER 7 OF 7
                       MEDLINE on STN
AN
     79216779
                  MEDLINE
DN
     PubMed ID: 222809
TI
     Gangliosides sensitize unresponsive fibroblasts to Escherichia
     coli heat-labile enterotoxin.
ΑU
     Moss J; Garrison S; Fishman P H; Richardson S H
SO
     The Journal of clinical investigation, (1979 Aug) Vol. 64, No.
     2, pp. 381-4.
     Journal code: 7802877. ISSN: 0021-9738.
     United States
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
     197909
EΜ
ED
     Entered STN: 15 Mar 1990
     Last Updated on STN: 15 Mar 1990
     Entered Medline: 25 Sep 1979
AB
     Chemically transformed mouse fibroblasts did not raise their cyclic AMP
     level in response to Escherichia coli heat-labile
     enterotoxin. These fibroblasts did, however, incorporate
     exogenous mono-, di-, and trisialogangliosides. After the uptake of
     monosialoganglioside galactosyl-N-acetylgalactosaminyl-[N-
     acetylneuraminyl]-galactosylglucosylceramide (GM1), the
     cells responded to E. coli heat-labile
     enterotoxin. The di- and trisialogangliosides were considerably
     less effective. GM1, the putative cholera toxin (choleragen) receptor,
     has been implicated previously as the receptor for E.
     coli heat-labile enterotoxin based on the ability of the
     free ganglioside to inhibit the effects of toxin. This investigation
     establishes that the ganglioside, when incorporated into fibroblasts,
     serves a functional role in mediating the responsiveness to the toxin.
CT
      Animals
      Cell Line
        Cholera Toxin: PD, pharmacology
     *Cyclic AMP: ME, metabolism
       *Enterotoxins: PD, pharmacology
       *Escherichia coli
      Fibroblasts: DE, drug effects
     *Fibroblasts: ME, metabolism
     *Gangliosides: PD, pharmacology
      Heat
      Mice
RN
     60-92-4 (Cyclic AMP); 9012-63-9 (Cholera Toxin)
CN
     0 (Enterotoxins); 0 (Gangliosides)
```

=> d 158 bib ab tot

- L58 ANSWER 1 OF 16 MEDLINE on STN
- AN 2007131051 MEDLINE
- DN PubMed ID: 17268859
- TI Conjugation of oligosaccharides by reductive amination to amine modified chondroitin oligomer and gamma-cyclodextrin.
- AU Weikkolainen Krista; Aitio Olli; Blomqvist Maria; Natunen Jari; Helin Jari
- CS Department of Biological and Environmental Sciences, University of Helsinki, P. O. Box 56, 00014, Helsinki, Finland.
- SO Glycoconjugate journal, (2007 Apr) Vol. 24, No. 2-3, pp. 157-65. Electronic Publication: 2007-02-01.

 Journal code: 8603310. ISSN: 0282-0080.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 200711
- ED Entered STN: 3 Mar 2007 Last Updated on STN: 9 Nov 2007 Entered Medline: 8 Nov 2007
- Carbohydrates present on cell surfaces participate in numerous biological AΒ recognition phenomena including cell-cell interactions, cancer metastasis and pathogen invasion. Therefore, synthetic carbohydrates have a potential to act as pharmaceutical substances for treatment of various pathological phenomena by inhibiting specifically the interaction between cell surface carbohydrates and their protein receptors (lectins). However, the inherently low affinity of carbohydrate-protein interactions has often been an obstacle for successful generation of carbohydrate based pharmaceuticals. Multivalent glycoconjugates, i.e. structures carrying several copies of the active carbohydrate sequence in a carrier molecule, have been constructed to overcome this problem. Here we present two novel types of multivalent carbohydrate conjugates based on chondroitin oligomer and cyclodextrin carriers. These carriers were modified to express primary amino groups, and oligosaccharides were then bound to carrier molecules by reductive amination. Multivalent conjugates were produced using the human milk type oligosaccharides LNDFH I (Lewis-b hexasaccharide), LNnT, and GlcNAcbetal-3Galbetal-4GlcNAcbetal-3Galbetal-4Glc.
- L58 ANSWER 2 OF 16 MEDLINE on STN
- AN 2006599489 MEDLINE
- DN PubMed ID: 16880000
- TI Binding of Haemophilus ducreyi to carbohydrate receptors is mediated by the 58.5-kDa GroEL heat shock protein.
- AU Pantzar Martina; Teneberg Susann; Lagergard Teresa
- CS Institute of Biomedicine, Department of Microbiology and Immunology, Goteborg University, PO Box 435, SE-40530, Goteborg, Sweden.
- SO Microbes and infection / Institut Pasteur, (2006 Aug) Vol. 8, No. 9-10, pp. 2452-8. Electronic Publication: 2006-07-07. Journal code: 100883508. ISSN: 1286-4579.
- CY France
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals

- EM 200702
- ED Entered STN: 11 Oct 2006

Last Updated on STN: 14 Feb 2007

Entered Medline: 13 Feb 2007

- AB The bacterium Haemophilus ducreyi causes the sexually transmitted disease chancroid, which is characterized by the appearance of mucocutaneous, persistent ulcers on the external genitals. To identify carbohydrate receptors that mediate the attachment of this pathogen to host cells, we investigated the binding of 35S-methionine-labeled H. ducreyi strains to a panel of defined glycosphingolipids that were separated on thin layer chromatography plates. H. ducreyi bound to lactosylceramide, gangliotriaosylceramide, gangliotetraosylceramide, neolactotetraosylceramide, the GM3 ganglioside, and sulfatide. To elucidate the role of the surface-located 58.5-kDa GroEL heat shock protein (HSP) of H. ducreyi in attachment, we investigated the binding of purified HSP to the same panel of glycosphingolipids. Our results suggest that the 58.5-kDa GroEL HSP of H. ducreyi is responsible for the attachment of this bacterium to the majority of the tested glycosphingolipids, and thus represents a potential bacterial adhesin.
- L58 ANSWER 3 OF 16 MEDLINE on STN
- AN 2006283542 MEDLINE
- DN PubMed ID: 16714580
- TI The major subunit, CfaB, of colonization factor antigen i from enterotoxigenic Escherichia coli is a glycosphingolipid binding protein.
- AU Jansson Lena; Tobias Joshua; Lebens Michael; Svennerholm Ann-Mari; Teneberg Susann
- CS Department of Medical Biochemistry, Institute of Biomedicine, Goteborg University, P.O. Box 440, S-405 30 Goteborg, Sweden.
- SO Infection and immunity, (2006 Jun) Vol. 74, No. 6, pp. 3488-97. Journal code: 0246127. ISSN: 0019-9567.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 200606
- ED Entered STN: 23 May 2006

Last Updated on STN: 16 Jun 2006

Entered Medline: 15 Jun 2006

AB Bacterial adherence to mucosal surfaces is an important virulence trait of pathogenic bacteria. Adhesion of enterotoxigenic Escherichia coli (ETEC) to the intestine is mediated by a number of antigenically distinct colonization factors (CFs). One of the most common CFs is CFA/I. This has a fimbrial structure composed of a major repeating subunit, CfaB, and a single tip subunit, CfaE. The potential carbohydrate recognition by CFA/I was investigated by binding CFA/I-fimbriated bacteria and purified CFA/I fimbriae to a large number of variant glycosphingolipids separated on thin-layer chromatograms. For both fimbriated bacteria and purified fimbriae, specific interactions

could be identified with a number of nonacid glycosphingolipids. These included glucosylceramide, lactosylceramide with phytosphingosine and/or

hydroxy fatty acids, neolactotetraosylceramide,

gangliotriaosylceramide, gangliotetraosylceramide, the H5 type 2 pentaglycosylceramide, the Lea-5 glycosphingolipid, the Lex-5 glycosphingolipid, and the Ley-6 glycosphingolipid. These glycosphingolipids were also recognized by recombinant E. coli expressing CFA/I in the absence of tip protein CfaE, as well

coli expressing CFA/I in the absence of tip protein CfaE, as well
as by purified fimbriae from the same strain. This demonstrates that the

glycosphingolipid-binding capacity of CFA/I resides in the major CfaB subunit.

- L58 ANSWER 4 OF 16 MEDLINE on STN
- AN 2004041592 MEDLINE
- DN PubMed ID: 14576169
- TI Carbohydrate recognition by enterohemorrhagic **Escherichia coli**: characterization of a novel glycosphingolipid from cat small intestine.
- AU Teneberg Susann; Angstrom Jonas; Ljungh Asa
- CS Institute of Medical Biochemistry, Goteborg University, SE 405 30 Goteborg, Sweden.. susann.teneberg@medkem.gu.se
- SO Glycobiology, (2004 Feb) Vol. 14, No. 2, pp. 187-96. Electronic Publication: 2003-10-23.

 Journal code: 9104124. ISSN: 0959-6658.
- CY England: United Kingdom
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 200410
- ED Entered STN: 27 Jan 2004 Last Updated on STN: 20 Oct 2004 Entered Medline: 19 Oct 2004
- A key virulence trait of pathogenic bacteria is the ability to bind to AB receptors on mucosal cells. Here the potential glycosphingolipid receptors of enterohemorrhagic Escherichia coli were examined by binding of 35S-labeled bacteria to glycosphingolipids on thin-layer chromatograms. Thereby a selective interaction with two nonacid glycosphingolipids of cat small intestinal epithelium was found. The binding-active glycosphingolipids were isolated and, on the basis of mass spectrometry, proton NMR spectroscopy, and degradation studies, identified as Galalpha3Galbeta4Glcbeta1Cer (isoglobotriaosylceramide) and Galalpha3Galalpha3Galbeta4Glcbeta1Cer. The latter glycosphingolipid has not been described before. The interaction was not based on terminal Galalpha3 because the bacteria did not recognize the structurally related glycosphingolipids Galalpha3Galalpha4Galbeta4Glcbeta1Cer and Galalpha3Galbeta4GlcNAcbeta3Galbeta4Glcbeta1Cer (B5 glycosphingolipid). However, further binding assays using reference glycosphingolipids showed that the enterohemorrhagic E. coli also bound to lactosylceramide with phytosphingosine and/or hydroxy fatty acids, suggesting that the minimal structural element recognized is a correctly presented lactosyl unit. Further binding of neolactotetraosylceramide, lactotetraosylceramide, the Le(a)-5 qlycosphingolipid, as well as a weak binding to gangliotriaosylceramide and gangliotetraosylceramide, was found in analogy with binding patterns that previously have been described for other bacteria classified as lactosylceramide-binding.
- L58 ANSWER 5 OF 16 MEDLINE on STN
- AN 2001698041 MEDLINE
- DN PubMed ID: 11744628
- TI Helicobacter pylori-binding gangliosides of human gastric adenocarcinoma.
- AU Roche N; Larsson T; Angstrom J; Teneberg S
- CS Institute of Medical Biochemistry, Goteborg University, P.O. Box 440, SE 405 30 Goteborg, Sweden.
- SO Glycobiology, (2001 Nov) Vol. 11, No. 11, pp. 935-44. Journal code: 9104124. ISSN: 0959-6658.
- CY England: United Kingdom
- DT (IN VITRO)

Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

- LA English
- FS Priority Journals
- EM 200203
- ED Entered STN: 18 Dec 2001 Last Updated on STN: 26 Mar 2002 Entered Medline: 25 Mar 2002
- Acidic and neutral glycosphingolipids were isolated from a human gastric AB adenocarcinoma, and binding of Helicobacter pylori to the isolated glycosphingolipids was assessed using the chromatogram binding assay. The isolated glycosphingolipids were characterized using fast atom bombardment mass spectrometry and by binding of antibodies and lectins. The predominating neutral glycosphingolipids were found to migrate in the dito tetraglycosylceramide regions as revealed by anisaldehyde staining and detection with lectins. No binding of H. pylori to these compounds was obtained. The most abundant acidic glycosphingolipids, migrating as the GM3 ganglioside and sialyl-neolactotetraosylceramide, were not recognized by the bacteria. Instead, H. pylori selectively interacted with slow-migrating, low abundant gangliosides not detected by anisaldehyde staining. Binding-active gangliosides were isolated and characterized by mass spectrometry, proton nuclear magnetic resonance, and lectin binding as sialyl-neolactohexaosylceramide (NeuAcalpha3Galbeta4GlcNAcbeta3Galbeta4GlcNAcbeta3Galbeta4Glcbeta1Cer) and ${\tt sialyl-neolactooctaosylceramide} \ \ ({\tt NeuAcalpha3Galbeta4GlcNAcbeta3Galbeta4Galbeta$ NAcbeta3Galbeta4GlcNAcbeta3Galbeta4GlcbetalCer).
- L58 ANSWER 6 OF 16 MEDLINE on STN
- AN 2001111860 MEDLINE
- DN PubMed ID: 11056399
- TI Isolectins from Solanum tuberosum with different detailed carbohydrate binding specificities: unexpected recognition of lactosylceramide by N-acetyllactosamine-binding lectins.
- AU Ciopraga J; Angstrom J; Bergstrom J; Larsson T; Karlsson N; Motas C; Gozia O; Teneberg S
- CS Institute of Biochemistry, Romanian Academy, P.O. Box 78 200 Bucharest, 2, Romania.
- SO Journal of biochemistry, (2000 Nov) Vol. 128, No. 5, pp. 855-67. Journal code: 0376600. ISSN: 0021-924X.
- CY Japan
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 200102
- ED Entered STN: 22 Mar 2001 Last Updated on STN: 18 Dec 2002 Entered Medline: 8 Feb 2001
- AB Glycosphingolipid recognition by two isolectins from Solanum tuberosum was compared by the chromatogram binding assay. One lectin (PL-I) was isolated from potato tubers by affinity chromatography, and identified by MALDI-TOF mass spectrometry as a homodimer with a subunit molecular mass of 63,000. The other (PL-II) was a commercial lectin, characterized as two homodimeric isolectins with subunit molecular masses of 52,000 and 55,000, respectively. Both lectins recognized N-acetyllactosamine-containing glycosphingolipids, but the fine details of their carbohydrate binding specificities differed. PL-II preferentially bound to glycosphingolipids with N-acetyllactosamine branches, as Galbeta4GlcNAcbeta6(Galbeta4GlcNAcbeta3)Galbeta4Glcbeta1C er. PL-I also recognized this glycosphingolipid, but bound equally well to the linear

glycosphingolipid Galbeta4GlcNAcbeta3Galbeta4GlcNAcbeta3Galbeta4GlcbetalCe r. Neolactotetraosylceramide and the B5 pentaglycosylceramide were also bound by PL-I, while other glycosphingolipids with only one N-acetyllactosamine unit were non-binding. Surprisingly, both lectins also bound to lactosylceramide, with an absolute requirement for sphingosine and non-hydroxy fatty acids. The inhibition of binding to both lactosylceramide and N-acetyllactosamine-containing glycosphingolipids by N-acetylchitotetraose suggests that lactosylceramide is also accomodated within the N-acetylchitotetraose/N-acetyllactosamine-binding sites of the lectins. Through docking of glycosphingolipids onto a three-dimensional model of the PL-I hevein binding domain, a Galbeta4GlcNAcbeta3Galbeta4 binding epitope was defined. Furthermore, direct involvement of the ceramide in the binding of lactosylceramide was suggested.

```
L58 ANSWER 7 OF 16 MEDLINE on STN
```

- AN 2001110159 MEDLINE
- DN PubMed ID: 11087709
- TI Inhibition of nonopsonic Helicobacter pylori-induced activation of human neutrophils by sialylated oligosaccharides.
- AU Teneberg S; Jurstrand M; Karlsson K A; Danielsson D
- CS Institute of Medical Biochemistry, Goteborg University, P.O. Box 440, SE 405 30 Goteborg, Sweden.
- SO Glycobiology, (2000 Nov) Vol. 10, No. 11, pp. 1171-81. Journal code: 9104124. ISSN: 0959-6658.
- CY ENGLAND: United Kingdom
- DT (IN VITRO)

 Journal; Article; (JOURNAL ARTICLE)

 (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 200102
- ED Entered STN: 22 Mar 2001 Last Updated on STN: 22 Mar 2001 Entered Medline: 2 Feb 2001
- Certain strains of Helicobacter pylori have nonopsonic AΒ neutrophil-activating capacity. Some H. pylori strains and the neutrophil-activating protein of H.pylori (HPNAP) bind selectively to gangliosides of human neutrophils. To determine if there is a relationship between the neutrophil-activating capacity and the ganglioside-binding ability, a number of H. pylori strains, and HPNAP, were incubated with oligosaccharides, and the effects on the oxidative burst of subsequently challenged neutrophils was measured by chemiluminescence and flow cytometry. Both by chemiluminescence and flow cytometry a reduced response was obtained by incubation of H.pylori with sialic acid-terminated oligosaccharides, whereas lactose had no effect. The reductions obtained with different sialylated oligosaccharides varied to some extent between the H. pylori strains, but in general 3'sialyllactosamine was the most efficient inhibitor. Challenge of neutrophils with HPNAP gave no response in the chemiluminescence assay, and a delayed moderate response with flow cytometry. Preincubation of the protein with 3'-sialyllactosamine gave a slight reduction of the response, while 3'-sialyllactose had no effect. The current results suggest that the nonopsonic H. pylori-induced activation of neutrophils occurs by lectinophagocytosis, the recognition of sialylated glycoconjugates on the neutrophil cell surface by a bacterial adhesin leads to phagocytosis and an oxidative burst with the production of reactive oxygen metabolites.

L58 ANSWER 8 OF 16 MEDLINE on STN

```
AN 2001060702 MEDLINE
```

- DN PubMed ID: 10965049
- TI Common architecture of the primary galactose binding sites of Erythrina corallodendron lectin and heat-labile enterotoxin from Escherichia coli in relation to the binding of branched neolactohexaosylceramide.
- AU Teneberg S; Berntsson A; Angstrom J
- CS Institute of Medical Biochemistry, Goteborg University, P.O. Box SE 405 30 Goteborg, Sweden.
- SO Journal of biochemistry, **(2000 Sep)** Vol. 128, No. 3, pp. 481-91. Journal code: 0376600. ISSN: 0021-924X.
- CY Japan
- DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 200012
- ED Entered STN: 22 Mar 2001 Last Updated on STN: 18 Dec 2002 Entered Medline: 22 Dec 2000
- AΒ The heat-labile enterotoxin from Escherichia coli (LT) is responsible for so-called traveller's diarrhea and is closely related to the cholera toxin (CT). Toxin binding to GM1 at the epithelial cell surface of the small intestine initiates the subsequent diarrheal disease. However, LT has a broader receptor specificity than CT in that it also binds to N-acetyllactosamine-terminated structures. The unrelated lectin from Erythrina corallodendron (ECorL) shares this latter binding property. findings that both ECorL and porcine LT (pLT) bind to lactose as well as to neolactotetraosylceramide suggests a common structural theme in their respective primary binding sites. Superimposing the terminal galactose of the lactoses in the respective crystal structures of pLT and ECorL reveals striking structural similarities around the galactose despite the lack of sequence and folding homology, whereas the interactions of the penultimate GlcNAcb3 in the neolactotetraosylceramide differ. The binding of branched neolactohexaosylceramide to either protein reveals an enhanced affinity relative to neolactotetraosylceramide. The b3-linked branch is found to bind to the primary Gal binding pocket of both proteins, whereas the b6-linked branch outside this site provides additional interactions in accordance with the higher binding affinities found for this compound. While the remarkable architectural similarities of the primary galactose binding sites of pLT and ECorL point to a convergent evolution of these subsites, the distinguishing structural features determining the overall carbohydrate specificities are located in extended binding site regions. In pLT, Arg13 is thus found to play a crucial role in enhancing the affinity not only for N-acetyllactosamineterminated structures but also for GM1 as compared to human LT (hLT) and CT. The physiological relevance of the binding of N-acetyllactosaminecontaining glycoconjugates to LT and ECorL is briefly discussed.
- L58 ANSWER 9 OF 16 MEDLINE on STN
- AN 1999054731 MEDLINE
- DN PubMed ID: 9832619
- TI Glycosphingolipid binding specificities of Neisseria meningitidis and Haemophilus influenzae: detection, isolation, and characterization of a binding-active glycosphingolipid from human oropharyngeal epithelium.
- AU Hugosson S; Angstrom J; Olsson B M; Bergstrom J; Fredlund H; Olcen P; Teneberg S

- CS Department of Otorhinolaryngology, Orebro Medical Center Hospital, Orebro, Sweden.
- SO Journal of biochemistry, (1998 Dec 1) Vol. 124, No. 6, pp. 1138-52. Journal code: 0376600. ISSN: 0021-924X.
- CY Japan
- DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T.)
- LA English
- FS Priority Journals
- EM 199903
- ED Entered STN: 24 Mar 1999 Last Updated on STN: 24 Mar 1999 Entered Medline: 9 Mar 1999
- AB The glycosphingolipid binding specificities of Haemophilus influenzae and Neisseria meningitidis were investigated as to the binding of radiolabeled bacteria to glycosphingolipids on thin-layer chromatograms. Thereby, similar binding profiles, for the binding of the two bacteria to lactosylceramide, isoglobotriaosylceramide, gangliotriaosylceramide, gangliotetraosylceramide, lactotetraosylceramide, neolactotetraosylceramide, and sialylneolactohexaosylceramide, were obtained. On a closer view the binding preferences of the bacteria could be differentiated into three groups. The first specificity is recognition of lactosylceramide. The second specificity is binding to gangliotriaosylceramide and gangliotetraosylceramide, since conversion of the acetamido group of the N-acetylgalactosamine of gangliotriaosylceramide and gangliotetraosylceramide to an amine prevented the binding of the bacteria, and thus the binding to these two glycosphingolipids represents a separate specificity from lactosylceramide recognition. Preincubation of H. influenzae with neolactotetraose inhibited the binding to neolactotetraosylceramide, while the binding to lactosylceramide, gangliotetraosylceramide, or lactotetraosylceramide was unaffected. Thus, the third binding specificity is represented by neolactotetraosylceramide, and involves recognition of other neolacto series glycosphingolipids with linear N-acetyllactosamine chains, such as sialylneolactohexaosylceramide. The relevance of the detected binding specificities for adhesion to target cells was addressed as to the binding of the bacteria to glycosphingolipids from human granulocytes, epithelial cells of human nasopharyngeal tonsils and human plexus choroideus. Binding-active neolactotetraosylceramide was thereby detected in human granulocytes and the oropharyngeal epithelium.
- L58 ANSWER 10 OF 16 MEDLINE on STN
- AN 97323395 MEDLINE
- DN PubMed ID: 9179843
- TI Structural basis for differential receptor binding of cholera and **Escherichia coli** heat-labile toxins: influence of heterologous amino acid substitutions in the cholera B-subunit.
- AU Backstrom M; Shahabi V; Johansson S; **Teneberg S**; Kjellberg A; **Miller-Podraza H**; Holmgren J; Lebens M
- CS Department of Medical Microbiology and Immunology, Goteborg University, Sweden.
- SO Molecular microbiology, (1997 May) Vol. 24, No. 3, pp. 489-97. Journal code: 8712028. ISSN: 0950-382X.
- CY ENGLAND: United Kingdom
- DT (COMPARATIVE STUDY)

(IN VITRO)

Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

- LA English
- FS Priority Journals
- EM 199708
- ED Entered STN: 25 Aug 1997

Last Updated on STN: 25 Aug 1997

Entered Medline: 13 Aug 1997

- The closely related B-subunits of cholera toxin (CTB) and AB Escherichia coli heat-labile enterotoxin (LTB) both bind strongly to GM1 ganglioside receptors but LTB can also bind to additional glycolipids and glycoproteins. A number of mutant CT B-subunits were generated by substituting CTB amino acids with those at the corresponding positions in LTB. These were used to investigate the influence of specific residues on receptor-binding specificity. A mutated CTB protein containing the first 25 residues of LTB in combination with LTB residues at positions 94 and 95, bound to the same extent as native LTB to both delipidized rabbit intestinal cell membranes, complex glycosphingolipids (polyglycosylceramides) and neolactotetraosylceramide, but not to non-GM1 intestinal glycosphingolipids. In contrast, when LTB amino acid substitutions in the 1-25 region were combined with those in the 75-83 region, a binding as strong as that of LTB to intestinal glycosphingolipids was observed. addition, a mutant LTB with a single Gly-33-->Asp substitution that completely lacked affinity for both GM1 and non-GM1 glycosphingolipids could still bind to receptors in the intestinal cell membranes and to polyglycosylceramides. We conclude that the extra, non-GM1 receptors for LTB consist of both sialylated and non-sialylated glycoconjugates, and that the binding to either class of receptors is influenced by different amino acid residues within the protein.
- L58 ANSWER 11 OF 16 MEDLINE on STN .
- AN 96375687 MEDLINE
- DN PubMed ID: 8781976
- TI Recognition of glycoconjugates by Helicobacter pylori: an apparently high-affinity binding of human polyglycosylceramides, a second sialic acid-based specificity.
- AU Miller-Podraza H; Milh M A; Bergstrom J; Karlsson K A
- CS Department of Medical Biochemistry, Goteborg University, Sweden.
- SO Glycoconjugate journal, (1996 Jun) Vol. 13, No. 3, pp. 453-60. Journal code: 8603310. ISSN: 0282-0080.
- CY ENGLAND: United Kingdom
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 199701
- ED Entered STN: 28 Jan 1997 Last Updated on STN: 28 Jan 1997 Entered Medline: 7 Jan 1997
- AB Helicobacter pylori has been reported to agglutinate erythrocytes and to bind to various other cells in a sialic acid-dependent way. The binding was inhibited by sialyllactose or fetuin and other sialylated glycoproteins. The specificity apparently requires bacterial growth on agar, since we found that it was lost after growth in the nutrient mixture Ham's F12. Instead, the bacteria bound with high affinity and in a sialic acid-dependent way to polyglycosylceramides of human erythrocytes, a still incompletely characterized group of complex glycolipids. Bacteria grown in F12 medium were metabolically labelled with 35S-methionine and analysed for binding to glycolipids on thin-layer chromatograms and to glycoproteins on blots after electrophoresis, with human erythrocyte glycoconjugates in focus. There was no binding to simpler gangliosides

including GM3 or sialylparagloboside, or to a mixture of brain gangliosides. In contrast, polyglycosylceramides of human erythrocyte membranes bound at a pmol level. The activity was eliminated by mild acid treatment, mild periodate oxidation or sialidase hydrolysis. Erythrocyte proteins as well as a range of reference glycoproteins did not bind except band 3, which was weakly active. However, this activity was resistant to periodate oxidation. These results indicate a second and novel sialic acid-recognizing specificity which is expressed independently of the previously described specificity.

```
L58 ANSWER 12 OF 16 MEDLINE on STN
```

- AN 95151768 MEDLINE
- DN PubMed ID: 7849044
- TI Enhanced binding of enterotoxigenic Escherichia coli K99 to amide derivatives of the receptor ganglioside NeuGc-GM3.
- AU Lanne B; Uggla L; Stenhagen G; Karlsson K A
- CS Department of Medical Biochemistry, Goteborg University, Sweden.
- SO Biochemistry, (1995 Feb 14) Vol. 34, No. 6, pp. 1845-50. Journal code: 0370623. ISSN: 0006-2960.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 199503
- ED Entered STN: 22 Mar 1995 Last Updated on STN: 22 Mar 1995 Entered Medline: 13 Mar 1995
- AΒ A natural receptor in pig small intestine [Teneberg, S., Willemsen, P., de Graaf, F. K., & Karlsson, K.-A. (1990) FEBS Lett. 263, 10-14] for the enterotoxigenic bacteria Escherichia coli K99 is the ganglioside NeuGc-GM3 (NeuGc alpha 3Gal beta 4Glc beta Cer) [e.g., Smit, W. Gaastra, J. P. Kamerling, J. F. G. Vliegenthart, & F. K. de Graaf (1984) Infect. Immun. 46, 578-584]. Chemical modifications of the carboxyl group of this ganglioside were performed, giving five different amides, the methyl ester, and the primary alcohol. The products were purified, and their structures were investigated by negative FAB mass spectrometry. Binding of E. coli K99 was tested by incubating 35S-labeled bacteria with derivatized compounds separated on thin-layer chromatograms. Modification of the carboxyl group to a primary amide strengthened the binding at least 5-fold, as estimated from autoradiography of dilutions on thin-layer plates. Some strengthening of the binding was also obtained with the methylamide as well as with the carboxyl group reduced to the alcohol. The ethylamide bound equally well as the underivatized NeuGc-GM3. Amide substituents as large as propyl amide and benzyl amide were still recognized by the bacteria, although they bound weaker. The methyl ester was not stable in the chromatogram-binding assay with silica gel and water present, and it reverted to the acid.
- L58 ANSWER 13 OF 16 MEDLINE on STN
- AN 95104315 MEDLINE
- DN PubMed ID: 7528675
- Tİ Alpha 2,3-sialyl and alpha 1,3-fucosyltransferase-dependent synthesis of sialyl Lewis x, an essential oligosaccharide present on L-selectin counterreceptors, in cultured endothelial cells.
- AU Majuri M L; Pinola M; Niemela R; Tiisala S; Natunen J; Renkonen O; Renkonen R
- CS Department of Bacteriology, University of Helsinki, Finland.

- SO European journal of immunology, (1994 Dec) Vol. 24, No. 12, pp. 3205-10. Journal code: 1273201. ISSN: 0014-2980.
- CY GERMANY: Germany, Federal Republic of
- DT (IN VITRO)

 Journal; Article; (JOURNAL ARTICLE)

 (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 199501
- ED Entered STN: 15 Feb 1995 Last Updated on STN: 6 Feb 1998 Entered Medline: 27 Jan 1995
- Sialyl Lewis x (sLex) oligosaccharides have been shown to be present in AB counterreceptors for L-selectin. We and others have previously shown that high endothelial cells in lymph nodes and at sites of inflammation express sLex. Here we show that also cultured human umbilical vein endothelial cells (HUVEC) express sLex on their cell surface. This oligosaccharide is formed by sequential action of alpha 2,3-sialyl- (alpha 2,3-ST) and alpha 1,3-fucosyltransferases (alpha 1,3-FT) on N-acetyllactosamine. At least two of the several alpha 2,3-ST and four of the several alpha 1,3-FT are present in HUVEC. In functional assays both alpha 2,3-ST and alpha 1,3-FT activities were observed in HUVEC lysates with exogenous lactosamine and sialyllactosamine acceptors, leading to the generation of the sialyllactosamine and sLex sequences, respectively. TNF stimulation increased the level of mRNA expression of FT VI, and the alpha 1,3-FT activity in HUVEC. Taken together these data show that endothelial cells express sLex and that they possess mRNA as well as enzyme activities of several alpha 2,3-ST and alpha 1,3-FT necessary in the final steps of sLex synthesis. Furthermore, inflammatory cytokines such as TNF can enhance transferase activities relevant in generating putative L-selectin counterreceptors.
- L58 ANSWER 14 OF 16 MEDLINE on STN
- AN 94129215 MEDLINE
- DN PubMed ID: 7507746
- TI Monoclonal antibody against a lactose epitope of glycosphingolipids binds to melanoma tumour cells.
- AU Ding K; Ekberg T; Zeuthen J; **Teneberg S; Karlsson K A**; Rosen A
- CS Department of Tumor Immunology, Wallenberg Laboratory, University of Lund, Sweden.
- SO Glycoconjugate journal, (1993 Oct) Vol. 10, No. 5, pp. 395-405. Journal code: 8603310. ISSN: 0282-0080.
- CY ENGLAND: United Kingdom
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 199403
- ED Entered STN: 18 Mar 1994
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 8 Mar 1994
- AB Mice were immunized with a neoglycoprotein consisting of a chemically modified carbohydrate moiety (reductively aminated 3'-sialyllactose) linked to human serum albumin. By this procedure an antibody response to the normally non-immunogenic carbohydrate structure was obtained. Hybridomas were established, and monoclonal antibodies were selected in ELISA based on their binding to the saccharide hapten, or to a lactosylceramide-mimicking neoglycolipid, lactose-bis-sulfone. One of the selected antibodies, 2H4, was of

particular interest, since it also bound to glycolipids present on melanoma cells. FACS analysis of a panel of 14 melanoma cell lines showed that the 2H4 antibody bound to the majority of these. In frozen, non-fixed sections or paraffin sections of biopsies the monoclonal antibody 2H4 stained melanoma cells, but not tumour infiltrating lymphocytes or normal skin. Detailed immunochemical analysis of 2H4, using thin layer chromatography revealed that it recognized an internal lactose epitope in several glycosphingolipids.

- L58 ANSWER 15 OF 16 MEDLINE on STN
- AN 86051591 MEDLINE
- DN PubMed ID: 3840699
- TI Mouse monoclonal antibodies with specificity for the melanoma-associated ganglioside disialyllactosylceramide (GD3) also react with the structural analogue disialylparagloboside.
- AU Brodin T; Hellstrom I; Hellstrom K E; Karlsson K A; Sjogren H O; Stromberg N; Thurin J
- SO Biochimica et biophysica acta, (1985 Dec 4) Vol. 837, No. 3, pp. 349-53. Journal code: 0217513. ISSN: 0006-3002.
- CY Netherlands
- DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
- LA English
- FS Priority Journals
- EM 198601
- ED Entered STN: 21 Mar 1990 Last Updated on STN: 21 Mar 1990 Entered Medline: 3 Jan 1986
- AB A mouse monoclonal IgM antibody, 4.2, has previously been shown to bind preferentially to the surface of human malignant melanoma cells and to have specificity for the GD3 ganglioside (NeuAc alpha 2---8NeuAc alpha 2---3Gal beta 1---4GlcCer). Using overlay of antibodies on thin-layer chromatograms with glycolipids of various sources, it was shown that antibody 4.2, a further IgM and two IgG3 mouse monoclonal antibodies, selected on the basis of reactivity with GD3, also bound with similar strength to the structural analogue NeuAc alpha 2---8NeuAc alpha 2---3Gal beta 1---4GlcNac beta 1---3Gal beta 1---4GlcCer or disialylparagloboside. The SK-MEL 28 melanoma cell line used for immunization was shown to contain a large amount of GD3 but to lack disialylparagloboside. The demonstrated cross-reactivity may be of importance when considering the use of these antibodies for biochemical and medical purposes.
- L58 ANSWER 16 OF 16 MEDLINE on STN
- AN 80006650 MEDLINE
- DN PubMed ID: 479198
- TI Structural characterization of lactotetraosylceramide, a novel glycosphingolipid isolated from human meconium.
- AU Karlsson K A; Larson G
- SO The Journal of biological chemistry, (1979 Sep 25) Vol. 254, No. 18, pp. 9311-6.
 - Journal code: 2985121R. ISSN: 0021-9258.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- EM 197911
- ED Entered STN: 15 Mar 1990

Last Updated on STN: 15 Mar 1990 Entered Medline: 21 Nov 1979 AB In the course of work on a systematic structural mapping of nonacid glycosphingolipids of human meconia, special attention was given to a major component preliminarily identified as an isomer of neolactotetraosylceramide (paragloboside). This component was isolated in its pure form from meconium of a blood group O individual and subjected to detailed structural analyses, using mass spectrometry and proton NMR spectroscopy on intact permethylated and permethylated-reduced (LiAlH4) derivatives, and gas liquid chromatography on degradational products of native, permethylated, and permethylated-reduced derivatives. The isolated compound was conclusively shown to have the structure Galp beta 1 yields 3GlcNAcp beta 1 yields 3Galp beta 1 yields 4Glcp beta 1 yields 1Cer, and is thus identified as lactotetraosylceramide. The major fatty acids were 2-hydroxy fatty acids with 16 and 20 to 24 carbon atoms, and the bases were sphingosine and phytosphingosine. This glycolipid, although not isolated and structurally characterized before, has long been thought of as a precursor substance of the Lewis active glycolipids and of ABH-active glycolipids with a type 1 saccharide chain.

=> => fil biosis FILE 'BIOSIS' ENTERED AT 13:04:07 ON 07 JAN 2008 Copyright (c) 2008 The Thomson Corporation

FILE COVERS 1926 TO DATE. CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 4 January 2008 (20080104/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

=> d all tot

- L80 ANSWER 1 OF 4 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
- AN 2005:275685 BIOSIS
- DN PREV200510055255
- TI Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea.
- AU Paton, Adrienne W.; Jennings, Michael P.; Morona, Renato; Wang, Hui; Focareta, Antonio; Roddam, Louise F.; Paton, James C. [Reprint Author]
- CS Univ Adelaide, Sch Mol and Biomed Sci, Adelaide, SA 5005, Australia james.paton@adelaide.edu.au
- SO Gastroenterology, (MAY 2005) Vol. 128, No. 5, pp. 1219-1228. CODEN: GASTAB. ISSN: 0016-5085.
- DT Article
- LA English
- ED Entered STN: 21 Jul 2005 Last Updated on STN: 21 Jul 2005
- AB Background & Aims: We have developed a therapeutic strategy for gastrointestinal infections that is based on molecular mimicry of host receptors for bacterial toxins on the surface of harmless gut bacteria. The aim of this study was to apply this to the development of a recombinant probiotic for treatment and prevention of diarrheal disease caused by enterotoxigenic Escherichia coli strains that produce heat-labile enterotoxin. Methods: This was achieved by expressing glycosyltransferase genes from Neisseria meningitidis or Campylobacter jejuni in a harmless Escherichia coli strain (CWG:308), resulting in the production of a chimeric lipopolysaccharide capable of binding heat-labile

enterotoxin with high avidity. Results: The strongest heat-labile enterotoxin binding was achieved with a construct (CWG308:pLNT) that expresses a mimic of lacto-N-neotetraose, which neutralized >= 93.8% of the heat-labile enterotoxin activity in culture lysates of diverse enterotoxigenic Escherichia coli strains of both human and porcine origin. When tested with purified heat-labile enterotoxin, it was capable of adsorbing approximately 5% of its own weight of toxin. Weaker toxin neutralization was achieved with a construct that mimicked the ganglioside Preabsorption with, or coadministration of, CWG308:pLNT also resulted in significant in vivo protection from heat-labile enterotoxin-induced fluid secretion in rabbit ligated ileal loops. Conclusions: Toxin-binding probiotics such as those described here have considerable potential for prophylaxis and treatment of enterotoxigenic Escherichia coli-induced travelers' diarrhea. Pathology - Therapy 12512 14004 Digestive system - Physiology and biochemistry Digestive system - Pathology 14006 Pharmacology - General 22002 Physiology and biochemistry of bacteria 31000 Medical and clinical microbiology - General and methods 36001 Major Concepts Pharmacology; Infection; Digestive System (Ingestion and Assimilation) Diseases diarrhea: digestive system disease, symptom Diarrhea (MeSH) Diseases gastrointestinal infection: digestive system disease, infectious Chemicals & Biochemicals enterotoxin; lacto-N-neotetraose ORGN Classifier Aerobic Helical or Vibrioid Gram-Negatives Eubacteria; Bacteria; Microorganisms Organism Name Campylobacter jejuni (species) Taxa Notes Bacteria, Eubacteria, Microorganism ORGN Classifier Enterobacteriaceae 06702 Facultatively Anaerobic Gram-Negative Rods; Eubacteria; Bacteria; Microorganisms Organism Name Escherichia coli (species): strain-CWG308 Bacteria, Eubacteria, Microorganism ORGN Classifier 86040 Leporidae Super Taxa Lagomorpha; Mammalia; Vertebrata; Chordata; Animalia Organism Name rabbit (common) Taxa Notes Animals, Chordates, Lagomorphs, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Vertebrate ORGN Classifier Neisseriaceae 06507 Gram-Negative Aerobic Rods and Cocci; Eubacteria; Bacteria;

CC

ΙT

ΙT

ΙΤ

ΙT

```
Microorganisms
     Organism Name
        Neisseria meningitidis (species)
     Taxa Notes
        Bacteria, Eubacteria, Microorganism
RN
     13007-32-4 (lacto-N-neotetraose)
L80
    ANSWER 2 OF 4 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ΑN
     2001:181018 BIOSIS
DN ·
     PREV200100181018
TΙ
     Nutritional formulations containing lacto-N-neotetraose.
ΑU
     Prieto, Pedro A. [Inventor]; Kroening, Terry A. [Inventor, Reprint author]
CS
     Gahanna, OH, USA
     ASSIGNEE: Abbott Laboratories
PΙ
     US 6083934 20000704
SO
     Official Gazette of the United States Patent and Trademark Office Patents,
     (July 4, 2000) Vol. 1236, No. 1. e-file.
     CODEN: OGUPE7. ISSN: 0098-1133.
DT
     Patent
LA
     English
ED
     Entered STN: 11 Apr 2001
     Last Updated on STN: 18 Feb 2002
AB
     A nutritional formulation containing an effective amount of
     Lacto-N-neoTetraose to simulate the growth and/or metabolic activity of
     Bifidobacterium is provided. A process of inhibiting bacterial infections
     caused by Bacteroides, Clostridium, and E. coli
     including the step of feeding the nutritional composition to a subject is
     also provided.
    514061000
NCL
CC
     General biology - Miscellaneous
                                       00532
TT
     Major Concepts
        Foods; Pediatrics (Human Medicine, Medical Sciences); Nutrition;
        Pharmacology
IT
     Diseases
        bacterial infection: bacterial disease
        Bacterial Infections (MeSH)
IT
     Chemicals & Biochemicals
        lacto-N-neotetraose: feeding, nutrient, nutritional formulations
ORGN Classifier
        Irregular Nonsporing Gram-Positive Rods
                                                   08890
     Super Taxa
        Actinomycetes and Related Organisms; Eubacteria; Bacteria;
        Microorganisms
     Organism Name
        Bifidobacterium: growth activity stimulation, metabolic activity
        stimulation
     Taxa Notes
        Bacteria, Eubacteria, Microorganisms
RN
     13007-32-4 (lacto-N-neotetraose)
L80
    ANSWER 3 OF 4 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ΑN
     1997:408381 BIOSIS
DN
     PREV199799714584
ΤI
     Immobilization of reducing sugars as toxin binding agents.
ΑU
     Nilsson, U. J.; Heerze, L. D.; Liu, Y.-C.; Armstrong, G. D.; Palcic, M.
     M.; Hindsgaul, O. [Reprint author]
CS
     Dep. Chem., Univ. Alberta, Edmonton, AB T6G 2G2, Canada
SO
     Bioconjugate Chemistry, (1997) Vol. 8, No. 4, pp. 466-471.
     CODEN: BCCHES. ISSN: 1043-1802.
```

DT

Article

```
LA
     English
ED
     Entered STN: 24 Sep 1997
     Last Updated on STN: 21 Nov 1997
AB
     A simple and economical procedure for the attachment of reducing sugars to
     aminated solid supports has been developed. Reaction of the amino groups
     on the solid support with p-nitrophenyl chloroformate, followed by
     1,6-hexanediamine, yields a chain-extended amine to which reducing sugars
     can be attached while remaining accessible to macromolecules.
     Immobilization of the reducing sugars involves a simple incubation
     followed by trapping of the resulting glycosylamine with acetic anhydride
     and recovery of the unreacted sugar by filtration. This technique was
     used to immobilize lactose and sialyllactose onto silylaminated Chromosorb
     P, producing solid supports that effectively neutralized the activity of
     cholera toxin from Vibrio cholerae and heat-labile enterotoxin of
     enterotoxigenic Escherichia coli. The general applicability of such solid
     supports for toxin neutralization was further demonstrated by
     immobilization of the enzymatically synthesized alpha-Gal(1-3)beta-Gal(1-
     4)Glc trisaccharide, which produced a support that efficiently neutralized
     toxin A of Clostridium difficile. The results from this study suggest
     that these solid supports have the potential to serve as inexpensive
     therapeutics for bacterial toxin-mediated diarrheal diseases.
CC
     Biochemistry studies - General
                                      10060
     Biochemistry studies - Carbohydrates
                                            10068
       Digestive system - Pathology
                                      14006
     Toxicology - General and methods
                                        22501
     Physiology and biochemistry of bacteria
                                               31000
     Medical and clinical microbiology - Bacteriology
                                                        36002
IT
     Major Concepts
        Biochemistry and Molecular Biophysics; Digestive System (Ingestion and
        Assimilation); Infection; Physiology; Toxicology
ΙT
     Chemicals & Biochemicals
        P-NITROPHENYL CHLOROFORMATE; 1,6-HEXANEDIAMINE; SIALYLLACTOSE; LACTOSE
     Miscellaneous Descriptors
ΙT
        EACTERIAL TOXINS; CHOLERA TOXIN; DIGESTIVE SYSTEM DISEASE; HOST;
        IMMOBILIZATION; LACTOSE; P-NITROPHENYL CHLOROFORMATE; PATHOGEN;
        REDUCING SUGAR; SIALYLLACTOSE; THERAPY PLANNING; TOXICITY; TOXICOLOGY;
        TOXIN A; TOXIN-MEDIATED DIARRHEA; 1,6-HEXANEDIAMINE
ORGN Classifier
                   33000
        Animalia
     Super Taxa
        Animalia
     Organism Name
        animal
        Animalia
     Taxa Notes
        Animals
ORGN Classifier
        Endospore-forming Gram-Positives
     Super Taxa
        Eubacteria; Bacteria; Microorganisms
     Organism Name
        endospore-forming gram-positive rods and cocci
        Clostridium difficile
     Taxa Notes
        Bacteria, Eubacteria, Microorganisms
ORGN Classifier
        Enterobacteriaceae
                             06702
     Super Taxa
        Facultatively Anaerobic Gram-Negative Rods; Eubacteria; Bacteria;
        Microorganisms
```

```
Organism Name
        Escherichia coli
     Taxa Notes
        Bacteria, Eubacteria, Microorganisms
ORGN Classifier
                       06704
        Vibrionaceae
     Super Taxa
        Facultatively Anaerobic Gram-Negative Rods; Eubacteria; Bacteria;
        Microorganisms
     Organism Name
        Vibrio cholerae
     Taxa Notes
        Bacteria, Eubacteria, Microorganisms
RN
     7693-46-1 (P-NITROPHENYL CHLOROFORMATE)
     124-09-4 (1,6-HEXANEDIAMINE)
     3001-89-6Q (SIALYLLACTOSE)
       35890-38-1Q (SIALYLLACTOSE)
     63-42-3 (LACTOSE)
     11040-27-0Q (SIALYLLACTOSE)
L80
    ANSWER 4 OF 4 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
     1995:300179 BIOSIS
ΑN
     PREV199598314479
DN
ΤI
     Inhibition of cholera toxin by human milk fractions and sialyllactose.
ΑU
     Idota, Tadashi; Kawakami, Hiroshi; Murakami, Yuji; Sugawara, Makihiro
CS
     Technical Res. Inst., Snow Brand Milk Products Co. Ltd., 1-1-2 Minamidai,
     Kawagoe, Saitama 350-11, Japan
SO
     Bioscience Biotechnology and Biochemistry, (1995) Vol. 59, No. 3, pp.
     417-419.
     ISSN: 0916-8451.
DT
     Article
     English
LA
ED
     Entered STN: 11 Jul 1995
     Last Updated on STN: 11 Jul 1995
     The effects of human milk fractions on cholera toxin B subunit binding to
AΒ
     monosialoganglioside 1 (G-M1) were investigated. Human milk, human
     defatted milk, whey, and a low-molecular-weight fraction of human milk
     inhibited the binding, but casein did not inhibit it. The inhibitory
     activity of whey from bovine-milk-based infant formula was less than that
     of whey from human milk. Differences in composition between human and
     bovine whey seemed to influence the extent of the inhibitory activity.
     Sialylated oligosaccharides were considered to be the possible components
     that inhibited cholera toxin. The effects of sialyllactose, a predominant
     sialylated component of human milk, on cholera toxin-induced
     diarrhea were investigated by the rabbit intestinal loop method.
     Sialyllactose inhibited the cholera toxin inducing fluid accumulation,
     although neither sialic acid nor lactose had an effect on it. The results
     suggest that sialyllactose is responsible for the inhibitory activity of
     milk on cholera toxin.
CC
     Comparative biochemistry
     Biochemistry methods - General
                                      10050
     Biochemistry methods - Proteins, peptides and amino acids
                                                                 10054
     Biochemistry methods - Carbohydrates
                                            10058
     Biochemistry studies - General
                                     10060
     Biochemistry studies - Proteins, peptides and amino acids
                                                                 10064
     Biochemistry studies - Lipids
                                    10066
     Biochemistry studies - Carbohydrates
                                            10068
     Biophysics - Methods and techniques
     Biophysics - Molecular properties and macromolecules
     Physiology - General
                            12002
```

```
Physiology - Comparative
Pathology - General 125
                                 12003
                            12502
     Pathology - Comparative
                                12503
     Nutrition - General studies, nutritional status and methods
     Nutrition - General dietary studies
                                            13214
     Nutrition - Proteins, peptides and amino acids
                                                       13224
     Digestive system - Physiology and biochemistry
                                                       14004
       Digestive system - Pathology
                                       14006
     Reproductive system - Physiology and biochemistry
                                                           16504
     Toxicology - General and methods
                                         22501
     Toxicology - Antidotes and prevention
                                              22505
     Physiology and biochemistry of bacteria
                                                31000
     Medical and clinical microbiology - General and methods
                                                                 36001
     Medical and clinical microbiology - Bacteriology
ΙT
     Major Concepts
        Biochemistry and Molecular Biophysics; Digestive System (Ingestion and
        Assimilation); Gastroenterology (Human Medicine, Medical Sciences);
        Infection; Methods and Techniques; Nutrition; Pathology; Physiology;
        Reproductive System (Reproduction); Toxicology
IT
     Chemicals & Biochemicals
        SIALYLLACTOSE
     Miscellaneous Descriptors
ΙT
        B SUBUNIT BINDING; BACTERIAL INFECTION; CASEIN; DIARRHEA;
        INHIBITORY ACTIVITY; LOW-MOLECULAR-WEIGHT FRACTION; RABBIT INTESTINAL
        LOOP METHOD; SIALYLATED OLIGOSACCHARIDES; WHEY
ORGN Classifier
        Hominidae
                    86215
     Super Taxa
        Primates; Mammalia; Vertebrata; Chordata; Animalia
     Organism Name
        Hominidae
     Taxa Notes
        Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGN Classifier
        Leporidae
                    86040
     Super Taxa
        Lagomorpha; Mammalia; Vertebrata; Chordata; Animalia
     Organism Name
        Leporidae
     Taxa Notes
        Animals, Chordates, Lagomorphs, Mammals, Nonhuman Vertebrates, Nonhuman
        Mammals, Vertebrates
ORGN Classifier
        Vibrionaceae
                       06704
     Super Taxa
        Facultatively Anaerobic Gram-Negative Rods; Eubacteria; Bacteria;
        Microorganisms
     Organism Name
        Vibrio cholerae
     Taxa Notes
        Bacteria, Eubacteria, Microorganisms
RN
     3001-89-6Q (SIALYLLACTOSE)
       35890-38-1Q (SIALYLLACTOSE)
     11040-27-0 (SIALYLLACTOSE)
=> => fil embase
FILE 'EMBASE' ENTERED AT 13:06:00 ON 07 JAN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.
```

FILE COVERS 1974 TO 7 Jan 2008 (20080107/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

=> d all

- L82 ANSWER 1 OF 1 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
- AN 2002044256 EMBASE
- TI Human milk oligosaccharides: A novel method provides insight into human genetics.
- AU Erney R.; Hilty M.; Pickering L.; Ruiz-Palacios G.; Prieto P.
- CS P. Prieto, Abbott Laboratories, Columbus, OH 43215, United States
- SO Advances in Experimental Medicine and Biology, (2001) Vol. 501, pp. 285-297.

Refs: 12

ISSN: 0065-2598 CODEN: AEMBAP

- CY United States
- DT Journal; Conference Article; (Conference paper)
- FS 022 Human Genetics

025 Hematology

029 Clinical and Experimental Biochemistry

- LA English
- SL English
- ED Entered STN: 14 Feb 2002 Last Updated on STN: 14 Feb 2002
- AB Human milk is a unique reservoir of oligosaccharides. The presence of many of these oligosaccharides is determined genetically and is related to the Lewis blood group and secretor antigen status of each donor. to quantitate neutral human milk oligosaccharides was developed. preparation was based on a single centrifugation-filtration step that yields oligosaccharide extracts. These extracts first were fractionated to remove a significant portion of their lactose content and were analyzed using high-pH anion-exchange chromatography. Oligosaccharide profiles from 386 milk samples obtained in this fashion generated quantitative information on lactose, the neutral cores lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNneoT), and the key fucosylated oligosaccharides. Additionally, the profiles provided genetic footprints of the Lewis and secretor status of the donors. Furthermore, unusual profiles that could not have been predicted from known genotypes were found. For this reason, milk glycoproteins were studied using carbohydrate-binding probes. Results confirm that oligosaccharides are an accurate predictor of the Lewis blood group status of the donor, and that glycosyltransferases have exquisite specificities. The data obtained in this study corroborate that Lewis-related antigens are tissue specific. This attribute of immunodominant carbohydrate sequences has significant implications for epidemiological studies of breast-fed infants.
- CT Medical Descriptors:

accuracy

```
anion exchange chromatography
     antigenicity
     biochemical composition
     blood group Lewis system
     *breast milk
     carbohydrate analysis
     centrifugation
     conference paper
     extract
     filtration
     fractionation
     genotype
     human
     human genetics
     prediction
     priority journal
     protein determination
     technique
CT
     Drug Descriptors:
     antigen: EC, endogenous compound
     carbohydrate: EC, endogenous compound
     glycoprotein: EC, endogenous compound
     glycosyltransferase: EC, endogenous compound
     lacto n neotetraose: EC, endogenous compound
     lacto n tetraose: EC, endogenous compound
     lactose: EC, endogenous compound
     *oligosaccharide: EC, endogenous compound
     unclassified drug
     (glycosyltransferase) 9033-07-2; (lacto n neotetraose) 13007-32-4
RN
     ; (lactose) 10039-26-6, 16984-38-6, 63-42-3, 64044-51-5
=> => d his
     (FILE 'HOME' ENTERED AT 12:30:48 ON 07 JAN 2008)
                SET COST OFF
     FILE 'REGISTRY' ENTERED AT 12:31:01 ON 07 JAN 2008
L1
              1 S 35890-39-2
L2
              1 S 35890-38-1
L3
              1 S 13007-32-4
     FILE 'MEDLINE' ENTERED AT 12:31:35 ON 07 JAN 2008
L4
              0 S L1
L5
            277 S ?SIALYLLACTOS? OR ?SIALYLL LACTOS? OR ?SIALYLACTOS? OR ?SIALY
L6
             30 S ACETYL(S) NEURAMIN?(S) LACTOS?
L7
            179 S ACETYLNEURAMIN? (S) LACTOS?
Γ8
              1 S NAN LACTOS?
L9
            425 S ?NEURAMINYLLACTOS? OR ?NEURAMIN? ?LACTOS?
L10
              1 S NAN LACTOS?
L11
            363 S ?NEURAMIN? ?LACTOS?
L12
             20 S LNNT
L13
             73 S NEOLACTOTETRAOS?
L14
            162 S LACTO (S) (NEOTETRAOS? OR NEO TETRAOS?)
L15
           1014 S L5-L14
L16
              6 S L15 AND (?DIARRH? OR ?DYSENTER? OR ?COLIC?)
                E DIARRHEA/CT
                E E3+ALL
          35903 S E5+NT
L17
                E E9+ALL
```

```
L18
            1224 S E6
                 E DIARRHEA/CT
                 E E4+ALL
                 E E2+ALL
L19
             367 S E41
                 E DIARRHEA/CT
                 E E5+ALL
                 E E9+ALL
            1577 S E9+NT
L20
                 E DYSENTERY/CT
                 E E3+ALL
L21
            9964 S E9+NT
                 E E8+ALL
L22
          116171 S E4+NT
                 E COLIC/CT
                 E E3+ALL
L23
            2978 S E36
L24
               1.S L15 AND L17-L23
L25
               6 S L16, L24
L26
              58 S L15 AND (ESCHERICHIA OR "E")()COLI
                 E ESCHERICHIA/CT
                 E E4+ALL
              43 S L15 AND E11+NT
L27
L28
              9 S L15 AND E32+NT
              44 S L15 AND E10+NT
L29
L30
              59 S L26-L29
                 E ENTEROTOXIN/CT
                 E E5+ALL
L31
              19 S L15 AND E4+NT
L32
              71 S L25, L30, L31
L33
              12 S L15 AND ?ENTEROTOX?
L34
              71 S L32, L33
                 E GASTROINTESTINAL DISEASE/CT
                 E E4+ALL
L35
              30 S L15 AND E3+NT
L36
              98 S L34, L35
              98 S L36 AND L1-L36
L37
              78 S L37 AND PY<=2002
L38
             20 S L37 NOT L38
L39
L40
              1 S L39 AND 2005246876/AN
L41
               2 S L38 AND (79216779 OR 95252586)/AN
               7 S L40, L41, L25 AND L1-L41
L42
L43
               3 S L42 AND ?CERAMID?
L44
               7 S L42, L43
                 E ANGSTROM/AU
L45
              59 S E5, E6
                 E TENEBERG/AU ·
L46
              60 S E4, E5
                 E SAARINEN/AU
L47
              81 S E3, E14-E16, E18
                 E SATOMAA/AU
L48
               3 S E6
                 E ROCHE/AU
L49
             15 S E3
                 E ROCHE N/AU
L50
             116 S E3-E6, E13
                 E NATUNEN/AU
L51
             15 S E4, E5
                 E MILLER PODRAZA/AU
L52
             46 S E4, E5
```

```
E MILLER H/AU
                E PODRAZA/AU
L53
              2 S E9
                E KARLSSON/AU
                E KARLSSON K/AU
L54
            391 S E3, E4
L55
             18 S E16-E18
                E ABUL/AU
                E ABUL M/AU
L56
             12 S E7, E8
                E ABULMILH/AU
L57
             16 S L15 AND L45-L56
L58
             16 S L57 AND L1-L57
     FILE 'MEDLINE' ENTERED AT 12:57:53 ON 07 JAN 2008
     FILE 'BIOSIS' ENTERED AT 12:58:22 ON 07 JAN 2008
     FILE 'MEDLINE' ENTERED AT 12:58:33 ON 07 JAN 2008
L59
             99 S L2 OR L3
L60
              1 S L59 AND (?DIARRH? OR ?DYSENTER? OR ?COLIC?)
L61
              0 S L59 AND L17-L23
L62
              4 S L59 AND (ESCHERICHIA OR "E")()COLI
L63
              4 S L59 AND ESCHERICHIA+NT/CT
L64
              1 S L59 AND ENTEROTOXINS+NT/CT
L65
              3 S L59 AND GASTROINTESTINAL DISEASES+NT/CT
L66
              8 S L60-L65
              7 S L66 NOT L44, L58
L67
     FILE 'BIOSIS' ENTERED AT 13:00:56 ON 07 JAN 2008
L68
             13 S L1
            170 S L2
L69
             48 S L3
L70
L71
            216 S L68-L70
             13 S L71 AND (ESCHERICHIA OR "E")()COLI
L72
L73
              3 S L71 AND (?DIARRH? OR ?DYSENTER? OR ?COLIC?)
L74
              2 S L71 AND ?ENTEROTOX?
L75
             14 S L72-L74
              2 S L75 AND (2001:181018 OR 1995:300179)/AN
L76
L77
              9 S 14006/CC AND L71
L78
              6 S L77 NOT L75
L79
              3 S L77 NOT L78
T80
              4 S L76, L79
     FILE 'BIOSIS' ENTERED AT 13:04:07 ON 07 JAN 2008
     FILE 'EMBASE' ENTERED AT 13:04:15 ON 07 JAN 2008
L81
             25 S L1-L3
L82
              1 S L81 AND 2002044256/AN
```

FILE 'EMBASE' ENTERED AT 13:06:00 ON 07 JAN 2008